Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Manhattan Associates Inc is a software-application business based in the US. Manhattan Associates shares (MANH) are listed on the NASDAQ and all prices are listed in US Dollars. Manhattan Associates employs 3,600 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Active traders
| Latest market close | $120.66 |
|---|---|
| 52-week range | $107.82 - $188.52 |
| 50-day moving average | $121.45 |
| 200-day moving average | $141.58 |
| Wall St. target price | $176.40 |
| PE ratio | 61.2834 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $1.87 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $120.66 from 2022-07-05
| 1 week (2022-06-30) | 5.29% |
|---|---|
| 1 month (2022-06-03) | N/A |
| 3 months (2022-04-07) | -11.94% |
| 6 months (2022-01-07) | -13.46% |
| 1 year (2021-07-07) | -18.27% |
|---|---|
| 2 years (2020-07-07) | 33.83% |
| 3 years (2019-07-05) | 71.49% |
| 5 years (2017-07-06) | 161.85% |
Valuing Manhattan Associates stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Manhattan Associates's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Manhattan Associates's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 61x. In other words, Manhattan Associates shares trade at around 61x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Manhattan Associates's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.479. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Manhattan Associates's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Manhattan Associates's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $150.4 million.
The EBITDA is a measure of a Manhattan Associates's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $685.7 million |
|---|---|
| Operating margin TTM | 20.84% |
| Gross profit TTM | $365.8 million |
| Return on assets TTM | 18.41% |
| Return on equity TTM | 56.15% |
| Profit margin | 17.27% |
| Book value | $3.44 |
| Market capitalisation | $7.2 billion |
TTM: trailing 12 months
We're not expecting Manhattan Associates to pay a dividend over the next 12 months.
Manhattan Associates's shares were split on a 4:1 basis on 12 January 2014. So if you had owned 1 share the day before before the split, the next day you'd have owned 4 shares. This wouldn't directly have changed the overall worth of your Manhattan Associates shares – just the quantity. However, indirectly, the new 75% lower share price could have impacted the market appetite for Manhattan Associates shares which in turn could have impacted Manhattan Associates's share price.
Over the last 12 months, Manhattan Associates's shares have ranged in value from as little as $107.82 up to $188.52. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Manhattan Associates's is 1.9011. This would suggest that Manhattan Associates's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Manhattan Associates, Inc. develops, sells, deploys, services, and maintains software solutions to manage supply chains, inventory, and omni-channel operations. It offers Manhattan SCALE, a portfolio of logistics execution solutions that provide trading partner management, yard management, optimization, warehouse management, and transportation execution services; and Manhattan Active, a set of enterprise and store omni-channel solutions. The company also provides inventory optimization, planning, and allocation solutions; maintenance services comprising customer support services and software enhancements; professional services, such as solutions planning and implementation, and related consulting services; and training and change management services. In addition, it resells computer hardware, radio frequency terminal networks, radio frequency identification chip readers, bar code printers and scanners, and other peripherals. The company offers products through direct sales personnel, as well as through partnership agreements with various organizations. It serves grocery, food and beverage, manufacturing, medical and pharmaceutical, retail, third-party logistics, and wholesale industries.
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.